JESSICA BOOKMAN: Open Payments
NPI 1518122266 · SEABROOK, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,898 in 171 payments from 13 companies in 2025. Trend: 2023 $937 · 2024 $3,517 · 2025 $4,898
Food & beverage: $4,858Education: $40
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 23 | $765 |
| Janssen Pharmaceuticals, Inc | 23 | $751 |
| Neurocrine BioSciences, Inc. | 18 | $638 |
| Otsuka America Pharmaceutical, Inc. | 19 | $555 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $548 |
| Lundbeck LLC | 21 | $457 |
| Axsome Therapeutics, Inc. | 14 | $352 |
| Vanda Pharmaceuticals Inc. | 17 | $303 |
| ABBVIE INC. | 8 | $223 |
| E.R. Squibb & Sons, L.L.C. | 7 | $138 |
Products named: REXULTI, INGREZZA, CAPLYTA, INVEGA SUSTENNA, Auvelity, ARISTADA, FANAPT, SPRAVATO.
Industry payments across NH — which companies pay providers there.
